Maciej Cieślak

Patent attorney trainee. Doctor of Chemical Sciences.

In cooperation with patent attorneys handles matters related to IP protection of inventions in the fields of chemistry, pharmacy and biotechnology, both in the national, regional and international procedure.

He has acquired extensive knowledge in medicinal chemistry, organic chemistry and the field of nanomedicine.

He graduated from the Faculty of Chemistry at the University of Gdansk, MSc in chemistry, field of study: biomedical chemistry. Gained professional experience through work at the Department of Biomedical Chemistry at the University of Gdansk and at the Institute of Organic Chemistry of the Polish Academy of Sciences in Warsaw. He completed scientific internships at the Institute of Experimental and Clinical Medicine of the Polish Academy of Sciences and at the Institute of Industrial Chemistry in Warsaw. He is an active member of COST Action Nano2Clinic (Cancer Nanomedicine - from the bench to the bedside), a group of people associated with nanomedicine and innovative therapies.

A laureate of the TopMinds mentoring program, which brings together scientists, entrepreneurs, as well as specialists in technology transfer and commercialization. He worked in the structures of the Polish Chemical Society and was a member of the Management Board of the Students' Section (2 years as Vice President). Coordinator of the Science Policy project and polish delegate in the European Young Chemists' Network (EYCN).

He completed his doctoral studies at the Institute of Organic Chemistry, Polish Academy of Sciences in Team XII headed by Prof. Zofia Lipkowska, PhD.
He was the principal investigator of the NCN grant "Design and synthesis of pH- or redox-sensitive dimeric dendrons as nanocarriers for siRNA or drug transport into glioma cells".
He conducted scientific research to design and develop a strategy for the synthesis of nanoparticle peptide dendrons and dendrimers and investigated the structures and properties of the obtained compounds. The biological target set for the obtained nanocompounds was diseases of the nervous system, in particular glioma cell lines.
He provides lectures and training in patent law and legal protection of inventions in the fields of chemistry, pharmacy and biotechnology.

Joined POLSERVICE in 2020.

Go back